Thermo Fisher: The Rerating Is Just Getting Started

An analyst assesses that TMO's stock is currently correctly priced by the market, trading at 19 times its estimated 2026 earnings per share, according to Bloomberg consensus estimates. This valuation suggests the market's current pricing accurately reflects the company's future earnings potential.

Analysis

Thermo Fisher Scientific (TMO) is currently assessed as being correctly priced by the market, trading at a forward price-to-earnings multiple of 19x based on Bloomberg consensus estimates for its 2026 earnings per share. This valuation suggests that the stock's current price reflects its anticipated future earnings potential, indicating a lack of obvious short-term mispricing. Despite this neutral valuation assessment, the analyst discloses a potential bullish bias, stating they may initiate a long position in TMO through stock or call options within the next 72 hours. This personal disclosure, while not a formal recommendation, hints at an underlying belief that the current "fair" price may still represent an attractive entry point for future upside, or that consensus estimates could prove conservative.

Key Decisions for Investors

• Investors holding TMO may view the 'correctly priced' assessment at 19x 2026 EPS as validation for maintaining their position, as the analysis does not present a compelling reason to sell.
• Potential investors should weigh the neutral valuation against the analyst's stated intent to potentially go long, suggesting that any new position should be based on a firm belief in long-term growth that justifies the current multiple.
• The analyst's consideration of call options suggests a possible strategy for bullish investors to gain exposure to TMO's potential upside while managing downside risk, especially given the stock is not considered undervalued.